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L E T T E R  T O  T H E  E D I T O R
Pregabalin: A range of misuse‐related unanswered questions
Although	initially	marketed	as	having	a	low	abuse	potential,	further	












(eg,	 glutamate,	 noradrenaline,	 and	 substance	 P,	 but	 not	 dopamine),	
acting	 against	 aberrant	 neuronal	 stimulation.2	 Several	 addictive	










of	 further	medications	 (eg,	 venlafaxine,	 bupropion,	 quetiapine,	 and	
loperamide),6	it	has	been	suggested	that	gabapentinoids	may	induce	
a	“liking”	(euphoric	high)	subjective	feeling,	due	to	their	gamma‐am‐












to	Bonnet	and	Scherbaum7	with	 respect	 to	 remaining	 recreational	
drugs	of	misuse,	there	is	less	evidence	for	gabapentinoids	being	mis‐





cases	appeared	to	be	quite	rare.7	Kapil	et	al9 used an online survey 
to	assess	the	self‐reported	lifetime	prevalence	of	misuse	of	GABA‐













Third,	 in	many	studies1,5	 it	was	unclear	 if	pregabalin	was	most	
typically	prescribed	 to	 those	affected	by	anxiety	 conditions	 to	ei‐





dose‐dependently	 associated	 with	 increase	 in	 extracellular	 GABA	
levels.7	Most	 likely,	 this	 drives	 the	 relaxation	 and	 euphoria	which	
are	reported	at	 the	commencement	of	prescribed	pregabalin	use.7 










benzodiazepines,	alcohol,	and	opioids.13,14	 In	all	 these	polydrug	 in‐
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